KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 1984.04

  -

  1986.04

  慶應義塾大学病院, 内科, 研修医

• 1986.05

  -

  1988.03

  川崎市立川崎病院, 内科, 医員

• 1988.10

  -

  1996.04

  国立がんセンター研究所, 分子腫瘍学部, 研究員

• 1988.10

  -

  1996.04

  国立がんセンター研究所, 分子腫瘍学部, 研究員

• 1993.03

  -

  1995.07

  Memorial Sloan-Kettering Cancer Center, Hematologic Oncology

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1978.04

  -

  1984.03

  Keio University, School of Medicine

  University, Graduated

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 医学博士, Keio University, 1991.02

  K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes.

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 医師免許, 1984.06

• 日本内科学会認定内科医, 1987.12

• 日本内科学会指導医, 2000.05

• 日本血液学会認定血液専門医, 2004.10

• 日本臨床腫瘍学会暫定指導医, 2005.09

display all >>

Books 【 Display / hide 】

Books 【 Display / hide 】

• Comprehensive review of Hematological Diseases

  服部　豊、松下麻衣子, メジカルビュー社, 2022.06,  Page： 366

  Scope: anti-neoplastic drugs,  Contact page： 125-130 Original author： 日本医師会 , Accepted

• フィジカルアセスメントに基づく症例解析と薬物治療

  青森達、大林恭子、齋藤義正、里美貴、須賀達夫、中村智徳、服部　豊、松下麻衣子, 京都廣川書店, 2021.08,  Page： 134

  Scope: 心不全の病態、慢性心不全の薬物治療,  Contact page： 10-14

• 臨床薬学テキストシリーズ　血液・造血器/感染症/悪性腫瘍

  望月眞弓・加藤裕久・服部　豊, 中山書店, 2021.05,  Page： 395

  Scope: 修得すべき知識の概要、血液疾患の検査,  Contact page： 2,3,15-25

• 多発性骨髄腫　新規治療薬の使い方・考え方

  HATTORI YUTAKA, 先端医学社（東京）, 2017.06

  Scope: 開発中の薬剤　pp174-179

• 骨髄腫治療を理解するためのMyeloma Biology

  HATTORI YUTAKA, 医薬ジャーナル社（大阪）, 2017.05

  Scope: 肝細胞増殖因子(HGF)およびその受容体(c-MET) pp137-144

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• A thermoresponsive cationic block copolymer brush-grafted silica bead interface for temperature-modulated separation of adipose-derived stem cells

  Nagase K., Okada A., Matsuda J., Ichikawa D., Hattori Y., Kanazawa H.

  Colloids and Surfaces B: Biointerfaces （Colloids and Surfaces B: Biointerfaces)  220 2022.12

  ISSN  09277765

  　View Summary

  Adipose-derived mesenchymal stem cells (ADSCs) have beneficial effects in cell transplantation therapy; these cells are collected from adipose tissue using low-invasive methods. However, to prepare ADSCs for cell therapy, a cell separation method that neither involves modification of the cell surface nor causes loss of cell activity is needed. Here, we aimed to develop ADSC separation columns using thermoresponsive cationic block copolymer brush-grafted beads as packing materials. The block copolymer brush was formed by a bottom cationic segment, poly(N,N-dimethylaminopropylacrylamide) (PDMAPAAm), and an upper thermoresponsive segment, poly(N-isopropylacrylamide) (PNIPAAm), and was grafted in two atom transfer radical polymerization reactions. The copolymer brush-grafted silica beads were packed into a column. An ADSC suspension was introduced into the columns at 37 °C and adsorbed on the copolymer brush-modified beads through electrostatic and hydrophobic interactions with the PDMAPAAm and PNIPAAm segments, respectively. The adsorbed ADSCs eluted from the column by lowering the temperature to 4 °C. In contrast, most Jurkat and vascular endothelial cells eluted at 37 °C, because of the relatively weaker electrostatic interactions with the block copolymer brush compared to ADSCs. Using the prepared column, a mixture of ADSCs and Jurkat cells was separated by changing the column temperature. The recovered ADSCs exhibited cell activity. The developed cell separation column may be useful for isolating ADSCs without cell surface modification, while maintaining cell activity.

  • Access to Document (DOI)

• PAX5-positive plasma cell leukemia presenting as lymphocytosis.

  Tateno S, Hirao M, Kikuchi T, Tsukada Y, Kunieda H, Osada M, Yamazaki K, Denda R, Hirose S, Matsushita M, Ichikawa D, Hattori Y

  [Rinsho ketsueki] The Japanese journal of clinical hematology （Japanese Society of Hematology)  63 （ 10 ） 1415 - 1420 2022.10

  Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted,  ISSN  0485-1439

  • Access to Document (DOI)

• Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease.

  Hirao M, Yamazaki K, Watanabe K, Mukai K, Hirose S, Osada M, Tsukada Y, Kunieda H, Denda R, Kikuchi T, Sugimori H, Okamoto S, Hattori Y.

  F1000 Research （Taylor & Francis)  11   245 - 245 2022.02

  Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

  • Access to Document (DOI)

• Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

  Yutaka Hattori · Takumi Futo · Ryo Uozaki · Daiju Ichikawa · Takashi Yamaguchi · Tomofumi Yamamoto · Maiko Matsushita · Maki Hirao

  International Journal of Hematology （Springer Nature)   2022.02

  Research paper (scientific journal), Joint Work, Accepted

  • Access to Document (DOI)

• SORT1/LAMP2-mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Lenalidomide Resistance in Multiple Myeloma

  Tomofumi Yamamoto, Jun Nakayama, Yusuke Yamamoto, Masahiko Kuroda, Yutaka Hattori, Takahiro Ochiya

  Blood Advance （American Society of Hematology)   2022.01

  Research paper (scientific journal), Accepted

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of novel combined immunotherapy using in silico screening system

  Hattori, Yutaka

  科学研究費補助金研究成果報告書 2020

• Molecular analysis and drug discovery targeting extramedullary disease in high-risk multiple myeloma

  Hattori, Yutaka

  科学研究費補助金研究成果報告書 2019

• Development of novel immunotherapy targeting leukemic stem cells.

  Hattori, Yutaka

  科学研究費補助金研究成果報告書 2016

• Drug discovery based on novel concept for overcoming high-risk myeloma which is still intractable despite of recent progress in the treatment

  Hattori, Yutaka

  科学研究費補助金研究成果報告書 2016

• Analysis on molecular mechanism of anti-tumor effect of thalidomide and exploitation of novel agents to overcome therapy-resistant multiple myeloma

  Hattori, Yutaka

  科学研究費補助金研究成果報告書 2011

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• Treatment of relapsed and refractory multiple myeloma

  Hisako Kunieda, Maki Hirao, Yutaka Hattori

  Hematological Malignancies (ver. 2) (Nihon Rinsho Co. Ltd)  78 ( 増刊号３ ) 638 - 644 2020.08

  Article, review, commentary, editorial, etc. (other), Joint Work

  　View Summary

  Treatment strategies and regimen for relapsed or refractory multiple myeloma are summarized. Newly developed drugs or methods were also introduced.

• A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma.

  Yamamoto T, Kosaka N, Hattori Y, Ochiya T.

  J Clin Med. 7 ( 3 ) E55 2018.03

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

• 下痢の受診勧奨のポイント

  HATTORI YUTAKA

  日本薬剤師会雑誌 (日本薬剤師会)  67 ( 10 ) 1439 - 1441 2015

  Article, review, commentary, editorial, etc. (scientific journal), Single Work

• 便秘の受診勧奨のポイント

  HATTORI YUTAKA

  日本薬剤師会雑誌 (日本薬剤師会)  67 ( 7 ) 957 - 961 2015

  Article, review, commentary, editorial, etc. (scientific journal), Single Work

• 多発性骨髄腫の生物学、最近の話題

  HATTORI YUTAKA

  臨床血液 (日本血液学会)  54 ( 8 ) 692 - 695 2013

  Article, review, commentary, editorial, etc. (scientific journal), Single Work

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• Drug repositioning revealed ambroxol induced myeloma cell death by inhibiting autophagy.

  Sugiyama H, Kaneko S, Fujihashi K, Shibata S, Matsumoto Y, IImura N, Endo S, Inoue M, Ichikawa D, Matsushita M, Yamazaki K, Hirao M, Hattori Y.

  The 84th Annual Meeting of the Japanese Society of Hematology, 

  2022.10

  , 

  Oral presentation (general)

• Development of komaroviquinone-derivatives that induce immune cell death of multiple myeloma.

  Kurita K, Matsushita M, Tamura K, Ichikawa D, Suto Y, Iwasaki G, Hattori Y.

  The 84th Annual Meeting of the Japanese Society of Hematology, 

  2022.10

  , 

  Poster presentation

• 多発性骨髄腫に対するKU-MEL-9を標的とした免疫療法の開発

  大月萌賀、松下麻衣子、須田ゆきの、斎藤朔、市川大樹、服部豊

  日本薬学会生物系薬学部会主催　第22回Pharmaco-Hematologyシンポジウム, 

  2022.06

  , 

  Oral presentation (general)

• 造血器腫瘍に対する治療のstate-of-the-arts　多発性骨髄腫

  服部　豊

  日本薬学会生物系薬学部会主催　第22回Pharmaco-Hematologyシンポジウム, 

  2022.06

  , 

  Oral presentation (invited, special)

• 髄外病変で高発現するリプログラミング因子がもたらす骨髄腫の病態への寄与

  唐崎翼、小山遼太郎、杉山裕夢、臼井凜、栗田昂希、市川大樹、松下麻衣子、山崎こう（白に告）平、平尾磨樹、服部豊

  日本薬学会生物系薬学部会主催　第22回Pharmaco-Hematologyシンポジウム, 

  2022.06

  , 

  Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 新たな概念によるハイリスク骨髄腫の予後不良に関わる分子機構の探索と克服薬の開発

  2020.04

  -

  2023.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

• Development of novel combined immunotherapy using in silico screening system

  2018.04

  -

  2021.03

  Grants-in-Aid for Scientific Research, Matsushita Maiko, Grant-in-Aid for Scientific Research (C), No Setting

  　View Summary

  In this sudy, we tried to identify immunomodulatory drugs for effectice combined immunotherapy against myeloma and other cancers, which are poorly responsive to immune-chkeckpoint inhibitors. We found that proteasome inhibitors could highly induce immunogenic cell death (ICD) in myeloma cells in vitro. Myeloma cells treated with these drugs could enhance maturation of dendritic cells and expansion of T cells. In addition, we isolated cytotoxic T cells against a novel tumor antigen expressed in various cancers, including myelama or pancreatic cancer. We successfully cloned T cell receptor genes and generated human T cell lines tranduced with these TCR genes. Combination thrapy of proteasome inhibiors and the antigen-specific TCR-transdeuced T cell transfusion would be expected in the future.

• ハイリスク造血器腫瘍の髄外病変に着目した新規ターゲットの探索と創薬研究

  2017.04

  -

  2020.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

• Drug discovery based on novel concept for overcoming high-risk myeloma which is still intractable despite of recent progress in the treatment

  2014.04

  -

  2017.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  　View Summary

  Despite of the use of newly developed drugs, multiple myeloma (MM) with high-risk cytogenetic changes revealed significantly poor prognosis. Most patients acquired drug resistance and developed extra-medullary diseases.We found that N-cadherin and other mesenchymal genes were highly expressed in t(4;14)-positive high-risk MM patients, and E-cadherin and other epithelial genes were expressed in MM patients with normal karyotype. Those cadherin-positive MM cells demonstrated tumorigenicity to SCID mice.We also developed a new immunomudulatory drug (IMiDs), TC11, which showed anti-tumor activity via cereblon-independent pathway unlike previously developed IMiDs.In addition, we tried structural modification of TC11 and succeeded in significantly increasing water-solublity of TC11.

• 難治性多発性骨髄腫に対する骨髄腫瘍血管新生を標的とした遺伝子治療法の開発と実践．

  2003.05

  -

  2004.03

  慶應義塾大学, Keio Gijuku Academic Development Funds, Research grant, No Setting

display all >>

Works 【 Display / hide 】

Works 【 Display / hide 】

• 教育上の業績

  HATTORI YUTAKA

  　

  , 

  Other

  　View Details

  Direct contribution to education of clinical residents in the management of in & out-patients of Keio University Hospital.

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• フェニルフタルイミド修飾体及びそれを有効成分とする抗癌剤

  Date applied： 2016-207402  2016.10 

  Patent, Joint

• 化合物もしくはその薬理学的に許容される塩、抗腫瘍剤、又は活性酸素産生剤

  Date applied： 特願2016-031897  2016.02 

  Date published： 特開2017-149658  2017.08 

  Patent, Joint

• ペプチド、樹状細胞、細胞傷害性T細胞、白血病ワクチン、及び白血病受動免疫療法剤

  Date applied： 特願2013-194119  2013.09 

  Date published： 特開2015-71543  2015.04 

  Date issued： 特許第6204130号  2017.09

  Patent, Joint

• がん免疫療法

  Date applied： 特願2012-132288  2012.06 

  Date published： 特開2013-256454  2013.12 

  Date issued： 特許第5984113号  2016.08

  Patent, Joint

• 多発性骨髄腫に伴う骨融解症状を診断するための診断剤及びその使用法.

  Date applied： P2011-17058  2011.01 

  Date published： 特開2012-159297  2012.08 

  Patent, Joint

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• がん集学的治療研究財団第29回一般研究助成

  服部豊., 2008.12, がん集学的治療研究財団, サリドマイドを用いた多発性骨髄腫に対する自家造血幹細胞移植後の維持・強化療法.

  　View Description

  　

• がん集学的治療研究財団第29回一般研究助成

  服部豊, 2008.12, がん集学的治療研究財団, サリドマイドを用いた多発性骨髄腫に対する自家造血幹細胞移植後の維持・強化療法.

• 日本白血病研究基金平成20年度一般研究賞

  服部豊., 2008.10, 日本白血病研究基金, 多発性骨髄腫の再発の分子機構とその克服.

  　View Description

  　

• 高松宮妃癌研究癌研究基金研究助成受賞

  服部豊., 2008.01, 高松宮妃癌研究癌研究基金, 難治性造血器腫瘍に対するポストサリドマイド世代の画期的治療法の開発.

  　View Description

  　

• がん集学的治療研究財団　第29回一般研究助成受賞

  2008

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• STUDY OF MAJOR FIELD: (CLINICAL PHYSIOLOGY AND THERAPEUTICS)

  2022

• SPECIALIZED CANCER CLINICAL TRAINING

  2022

• SEMINAR: (CLINICAL PHYSIOLOGY AND THERAPEUTICS)

  2022

• RESEARCH FOR BACHELOR'S THESIS 1

  2022

• PRIOR LEARNING FOR CLINICAL PRACTICE 5

  2022

display all >>

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• The Pharmaceutical Society of Japan, 

  2008

  -

  Present

• The Japanese Society of Myeloma, 

  2005

  -

  Present

• American Society of Hematology, 

  1995

  -

  Present

• The Japanese Cancer Association, 

  1988

  -

  Present

• The Japanese Society of Hematology, 

  1985

  -

  Present

display all >>

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2023.04

  -

  2024.03

  president, The 48th Annual Meeting of the Japanese Society of Hematology

• 2022.04

  -

  2023.03

  Chairman, The pharmaceutical Society of Japan, the 22th Pharmaco-Hematology Symposium

• 2005

  -

  Present

  director, Japanese Society of Myeloma

• 2000

  -

  Present

  Editorial Board, Japanese Journal of Clinical Oncology

• 1985

  -

  Present

  Board of Councillors、Editorial provision committee , Japanese Society of Hematology